imatinib mesylate has been researched along with Papulosquamous Disorders in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nambudiri, VE; Shi, CR | 1 |
| Baskaynak, G; Dörken, B; Kreuzer, KA; le Coutre, P; Schwarz, M | 1 |
2 other study(ies) available for imatinib mesylate and Papulosquamous Disorders
| Article | Year |
|---|---|
Imatinib-induced psoriasiform eruption in a patient with chronic myeloid leukemia.
Topics: Adult; Antineoplastic Agents; Drug Eruptions; Female; Hand Dermatoses; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Targeted Therapy; Protein Kinase Inhibitors; Scalp Dermatoses; Skin Diseases, Papulosquamous | 2018 |
Imatinib-induced acute generalized exanthematous pustulosis (AGEP) in two patients with chronic myeloid leukemia.
Topics: Adult; Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Pyrimidines; Skin Diseases, Papulosquamous | 2002 |